Oragenics Company History and Leadership Team

Dr. Jeffrey Hillman, Chief Scientific Officer of Oragenics, Inc., began his basic research into controlling the balance of good bacteria in dental plaque in the late 1970s at the Harvard-affiliated Forsyth Institute in Boston. He transferred his research to the University of Florida College of Dentistry in 1992. Dr. Hillman and Dr. Robert Zahradnik founded Oragenics at the end of 1996 to commercialize the fruits of more than 25 years of Dr. Hillman's research. Oragenics, Inc. is a publicly traded biotechnology company with a significant pipeline of seven proprietary product and platform technologies, all discovered by Dr. Hillman and all addressing major global healthcare needs. The Company consists of four Divisions: Consumer, which includes products for oral care, such as Teddy's Pride and EvoraPlus; Biologics, with the SMaRT Replacement Therapy that potentially could provide lifetime protection against tooth decay; Pharmaceutical, which focuses on the development of novel antibiotics for clinically important infections; and Diagnostics, with two biomarker platforms that target infectious diseases and cancer.